Novel genetic and epigenetic alterations in ... - Ous-research.no

More documents

Recommendations

Info

ReferencesT, Song X, Day RH, Sledziewski AZ, Lofton-Day C (2008) Sensitive Detection ofColorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay.PLoS ONE 3(11): e3759179. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, SomerfieldMR, Hayes DF, Bast RC, Jr. (2006) ASCO 2006 update of recommendations forthe use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33): 5313-5327180. Løvig T, Meling GI, Diep CB, Thorstensen L, Norheim AS, Lothe RA, Rognum TO(2002) APC and CTNNB1 mutations in a large series of sporadic colorectalcarcinomas stratified by the microsatellite instability status. Scand JGastroenterol 37(10): 1184-1193181. Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA (2003)Genetic tumor markers with prognostic impact in Dukes' stages B and Ccolorectal cancer patients. J Clin Oncol 21(5): 820-829182. Børresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E(1998) TP53 and long-term prognosis in colorectal cancer: mutations in the L3zinc-binding domain predict poor survival. Clin Cancer Res 4(1): 203-210183. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J,Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E,Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, TroungosC, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, RapalloA, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, OnoY, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Løvig T,Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO,Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ,Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D,Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J,Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S,Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectalcancer: the 'RASCAL II' study. Br J Cancer 85(5): 692-696184. Lewis KA, Bakkum-Gamez J, Loewen R, French AJ, Thibodeau SN, Cliby WA(2007) Mutations in the ataxia telangiectasia and rad3-related-checkpointkinase 1 DNA damage response axis in colon cancers. Genes ChromosomesCancer 46(12): 1061-1068185. Fernandez-Peralta AM, Nejda N, Oliart S, Medina V, Azcoita MM, Gonzalez-Aguilera JJ (2005) Significance of mutations in TGFBR2 and BAX in neoplasticprogression and patient outcome in sporadic colorectal tumors with highfrequencymicrosatellite instability. Cancer Genet Cytogenet 157(1): 18-24186. Jung B, Smith EJ, Doctolero RT, Gervaz P, Alonso JC, Miyai K, Keku T, SandlerRS, Carethers JM (2006) Influence of target gene mutations on survival, stage82
Referencesand histology in sporadic microsatellite unstable colon cancers. Int J Cancer118(10): 2509-2513187. Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH,Gaco V, Hass HG, Arkenau HT, Hartmann JT, Porschen R, Gregor M, Klump B(2007) Studies on p53, BAX and Bcl-2 protein expression and microsatelliteinstability in stage III (UICC) colon cancer treated by adjuvantchemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer96(9): 1409-1418188. Gao J, Zhang H, Arbman G, Sun XF (2008) RAD50/MRE11/NBS1 proteins inrelation to tumour development and prognosis in patients with microsatellitestable colorectal cancer. Histol Histopathol 23(12): 1495-1502189. Martineau-Thuillier S, Andreassen PR, Margolis RL (1998) Colocalization of TD-60and INCENP throughout G2 and mitosis: evidence for their possibleinteraction in signalling cytokinesis. Chromosoma 107(6-7): 461-470190. Mollinari C, Reynaud C, Martineau-Thuillier S, Monier S, Kieffer S, Garin J,Andreassen PR, Boulet A, Goud B, Kleman JP, Margolis RL (2003) Themammalian passenger protein TD-60 is an RCC1 family member with anessential role in prometaphase to metaphase progression. Dev Cell 5(2): 295-307191. Di NF, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De DS,Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is requiredfor response to panitumumab or cetuximab in metastatic colorectal cancer. JClin Oncol 26(35): 5705-5712192. Lievre A, Bachet JB, Le CD, Boige V, Landi B, Emile JF, Cote JF, Tomasic G,Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRASmutation status is predictive of response to cetuximab therapy in colorectalcancer. Cancer Res 66(8): 3992-3995193. Pegg AE (1990) Mammalian O6-alkylguanine-DNA alkyltransferase:regulation and importance in response to alkylating carcinogenic andtherapeutic agents. Cancer Res 50(19): 6119-6129194. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V,Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT andthe clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350-1354195. Nagasaka T, Sharp GB, Notohara K, Kambara T, Sasamoto H, Isozaki H, MacPheeDG, Jass JR, Tanaka N, Matsubara N (2003) Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrenceafter chemotherapy in colorectal cancer cases. Clin Cancer Res 9(14): 5306-531283
Page 1 and 2:
Novel genetic and epigenetic altera
Page 3 and 4:
TABLE OF CONTENTSACKNOWLEDGEMENTS .
Page 5 and 6:
ACKNOWLEDGEMENTSThe present work ha
Page 7 and 8:
Prefacetechnology[3]. This new tech
Page 10 and 11:
SummaryThe subgroup of carcinomas w
Page 12 and 13:
Introduction“Epigenetic inheritan
Page 14 and 15:
Introductionamino acid change it is
Page 16 and 17:
Introductionmethylation during embr
Page 18 and 19:
IntroductionDNA is most of the time
Page 20 and 21:
IntroductionFigure 5. DNA methylati
Page 22 and 23:
IntroductionFigure 6. Incidence rat
Page 24 and 25:
IntroductionFigure 8. Tumor staging
Page 26 and 27:
Introductioninasmuch as 80% of colo
Page 28 and 29:
IntroductionInstabilities involved
Page 30 and 31:
Introductionthere seems to be a fid
Page 32 and 33: Introductionsevere alterations are
Page 34 and 35: Introductionpopulation-wide screeni
Page 36 and 37: IntroductionFigure 12. Present and
Page 38 and 39: RESULTS IN BRIEFPaper Ia. “DNA hy
Page 40 and 41: Results in Briefinstability, and se
Page 42 and 43: Results in BriefUnivariate survival
Page 44 and 45: Discussionseveral factors, and full
Page 46 and 47: Discussionlow threshold, we increas
Page 48 and 49: DiscussionIt may seem like unnecess
Page 50 and 51: Discussionthan 96% DHPLC do not sta
Page 52 and 53: DiscussionFigure 13. Mutation detec
Page 54 and 55: DiscussionClinical impact of molecu
Page 56 and 57: Discussionmarkers with a very high
Page 58 and 59: Discussionchromosomes in metaphase[
Page 60 and 61: DiscussionThese examples underline
Page 62 and 63: Discussiongenes. One is based on mu
Page 64 and 65: CONCLUSIONSWe have identified novel
Page 66 and 67: Future PerspectivesMolecular risk a
Page 68 and 69: REFERENCES1. Breasted J (1930) The
Page 70 and 71: References29. Deng G, Chen A, Pong
Page 72 and 73: References57. Al-Sukhni W, Aronson
Page 74 and 75: References84. Kunkel TA (1993) Nucl
Page 76 and 77: ReferencesLeggett B, Levine J, Kim
Page 78 and 79: References133. Lind GE, Thorstensen
Page 80 and 81: References156. Meling GI, Lothe RA,
Page 84 and 85: References196. Honda S, Haruta M, S
Page 86 and 87: ORIGINAL ARTICLESAPPENDIXAppendix I
Page 89 and 90: GASTROENTEROLOGY 2007;132:1631-1639
Page 91: Paper IbGuro E Lind, Terje Ahlquist
Page 94 and 95: Journal of Translational Medicine 2
Page 105: Paper IITerje Ahlquist, Guro E Lind
Page 108 and 109: BackgroundMost cases of colorectal
Page 110 and 111: ADAMTS1 CDKN2A CRABP1 HOXA9 MAL MGM
Page 112 and 113: pseudogene, leading to a high rate
Page 114 and 115: strands. Proc Natl Acad Sci U S A 1
Page 116 and 117: concomitant absence of transcript a
Page 119 and 120: Volume 10 Number 7 July 2008 pp. 68
Page 121 and 122: 682 RAS Signaling in Colorectal Car
Page 127: Table W2. Detailed Somatic Events o
Page 131 and 132: Identification of RCC2 as a prognos
Page 133 and 134:
INTRODUCTIONMicrosatellite instabil
Page 135 and 136:
unselected series of primary tumors
Page 137 and 138:
specificity, i.e. that they only am
Page 139 and 140:
On the assumption that DNA repair a
Page 141 and 142:
In order to ensure that gene mutati
Page 143 and 144:
Figure 2. Mutation frequency differ
Page 145 and 146:
and TAF1B (0.50), ACVR2A and ASTE1
Page 147 and 148:
Multivariate analysesA multivariate
Page 149 and 150:
When comparing our findings of muta
Page 151 and 152:
The test series included a low numb
Page 153 and 154:
entering M-phase remains to be seen
Page 155 and 156:
12. Duval A, Reperant M, Hamelin R
Page 157 and 158:
34. Martineau-Thuillier S, Andreass
Page 159:
AppendicesAppendix I:List of abbrev
Page 163 and 164:
Critical Reviews TM in Oncogenesis,
Page 165 and 166:
TARGET GENES OF MSI COLORECTAL CANC
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191:
show all

Novel genetic and epigenetic alterations in ... - Ous-research.no

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?